美妆品牌抢滩药店新渠道

Core Insights - The article discusses the growing trend of domestic beauty brands entering the OTC (over-the-counter) channel in China, with 2025 being marked as a pivotal year for this transition [2][3] - Major players like Proya and other beauty companies are preparing to launch products in the OTC space, which is seen as a way to leverage the professional credibility of pharmacies and meet specific skincare needs [4][5] Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, expanding the current limited presence of leading brands [2] - Proya announced its entry into the OTC channel in January 2026, joining other brands that have already established a presence [2][4] - The OTC channel has seen significant sales, with brands like Winona achieving nearly 1 billion yuan in sales from this channel in 2023 [3] Group 2: Strategic Partnerships and Product Development - Companies are focusing on strategic partnerships and product development tailored for the OTC market, with Proya preparing multiple products aimed at post-operative recovery and daily skincare [4] - Winona and other brands are actively seeking to enhance their product offerings and market reach through collaborations with pharmacies [3][4] Group 3: Market Potential and Challenges - The OTC channel is projected to have about double the growth potential, with Winona aiming to cover 250,000 pharmacies [5] - The regulatory environment is becoming more favorable for pharmacies to sell cosmetic products, which aligns with the increasing demand for beauty products in these settings [6] - Despite the opportunities, there is a significant talent shortage in the OTC channel, as brands require personnel who are knowledgeable in both pharmaceuticals and cosmetics [7] Group 4: Financial Metrics and Profitability - The average gross margin for medical beauty products in the OTC channel is significantly higher than that of regular cosmetic products, with margins for medical dressings ranging from 77% to 83% [6] - Specific companies report high gross margins, such as 84.22% for Chuerjia's medical device products and 82% for Jinjian Biological's collagen products [6]